Citations

Clear

1792 citation(s) found for "Stephanie".

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study
Bo‐Subait, Stephanie, Logan, Brent R. , Smith, Sarah , Leckrone, Erin , Stefanski, Heather, Malmberg, Craig, Modi, Dipenkumar , Meade, Javier Bolaños, Rao, Uttam K. , Milner, Jordan , Jamieson, Katarzyna , Carrum, George, Kosuri, Satyajit, Cook, Rachel J. , Ballen, Karen K. , Loren, Alison W. , Arai, Sally , Choi, Sung Won , Shaw, Bronwen E. , Larkin, Karilyn , Malki, Monzr M. Al , Auletta, Jeffery J. , Spellman, Stephen R. , Askar, Medhat , Cusatis, Rachel , Shaffer, Brian C. , Khimani, Farhad , Gooptu, Mahasweta , Hamadani, Mehdi , Maiers, Martin , Stanek, Joseph , Abboud, Ramzi , Dholaria, Bhagirathbhai , Hogan, William J. , Reshef, Ran , Qayed, Muna , Broglie, Larisa , Devine, Steven M. , Jiménez, Antonio

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 936-936

10.1182/blood-2025-936 Get It

Abstract Allogeneic hematopoietic cell transplantation (HCT) remains inaccessible to many patients, particularly those of non-European ancestry, due to the limited availability of matched unrelated donors (URD). While single-HLA mismatched donors (7/8) often yield acceptable outcomes, URD HCT mismatched at ≥ 2 HLA alleles (<7/8) has historically been associated with poor survival and prohibitive toxicity. Post-transplant cyclophosphamide (PTCy) has improved outcomes following mismatched unrelated donor (MMUD) HCT, potentially enabling less stringent donor matching. Whether the degree of donor-recipient HLA disparity remains prognostic after MMUD HCT when PTCy is used is unknown. The ACCESS trial (NCT04904588) was conducted by the Center for International Blood and Marrow Transplant Research Clinical Research Organization and prospectively evaluated PTCy-based graft versus host disease (GVHD) prophylaxis in adult recipients of 4–7/8 (HLA-A, -B, -C and -DRB1) MMUD peripheral blood stem cells (PBSC) from donors age ≤35 years old following either myeloablative (MAC) or reduced intensity/non-myeloablative (RIC/NMA) conditioning. This analysis focused on all adult recipients of <7/8 grafts enrolled on the study across both conditioning strata, with descriptive comparison to patients who received 7/8 MMUD PBSC grafts. The primary endpoint was 1-year overall survival (OS). Secondary endpoints included primary graft failure (PGF), non-relapse mortality (NRM), relapse, acute and chronic GVHD, and GVHD-free relapse-free survival (GRFS). A total of 268 adults received MMUD PBSC grafts: 85 with <7/8 matches (MAC: n=23; RIC/NMA: n=62) and 183 with 7/8 matches (MAC: n=52; RIC/NMA: n=131). Among <7/8 recipients, median age was 57 years old (range, 24–78), 49% were male, with diagnoses of acute myeloid leukemia (AML) (55%), myelodysplastic syndromes (MDS) (15%), and lymphoma (14%). HLA mismatch distribution in the <7/8 group was 6/8 in 82%, 5/8 in 14%, and 4/8 in 4%. Most received fludarabine/melphalan (44%) or myeloablative busulfan/fludarabine (21%). Median CD34+ cell dose was 5.5 ×10^6/recipient kg (range: 3.2-8.0) and 75% of grafts were cryopreserved prior to infusion. Median donor age was 25.8 (range: 18.7-35.7) in the 7/8 group and 25.0 (range: 18.3-34.8) in the <7/8 group. The <7/8 cohort was racially and ethnically diverse, with 61% identifying as other than non-Hispanic white. The 7/8 cohort had a median age of 63 years old (range, 20–79), with 52% male. Disease distribution, conditioning intensity, and infused cell doses were similar to the <7/8 group. A smaller proportion of grafts were cryopreserved (61%), and 47% of patients identified as other than non-Hispanic White. One-year OS for <7/8 recipients was 86% (95% CI: 76–92%), compared to 79% (95% CI: 72–84%) in 7/8 recipients. One-year incidence of relapse was 23% (95% CI: 14–33%) in the <7/8 group and 17% (95% CI: 12–23%) in 7/8 recipients; NRM was 8% (95% CI: 4–16%) and 14% (95% CI: 9–19%), respectively. GRFS was 55% (95% CI: 43–65%) for <7/8 and 51% (95% CI: 44–58%) for 7/8 recipients. PGF occurred in 8% (95% CI: 3–18%) of <7/8 RIC recipients and 3% (95% CI: 1–8%) of 7/8 RIC recipients; no MAC recipients had PGF. At 6 months post-HCT, grade II–IV acute GVHD occurred in 34% (95% CI: 24–44%) of <7/8 patients and 39% (95% CI: 32–46%) of 7/8; grade III–IV acute GVHD was observed in 7% (95% CI: 3–14%) and 8% (95% CI: 5–13%), respectively. Moderate to severe chronic GVHD (NIH consensus criteria) at one year occurred in 8% (95% CI: 3–15%) of <7/8 recipients and 11% (95% CI: 7–16%) of 7/8 recipients. When grouped by conditioning intensity, 1-year outcomes within the <7/8 cohort were: OS 91% after MAC and 84% after RIC/NMA; relapse in 32% after MAC and 20% after RIC/NMA, respectively; GRFS was 53% for MAC and 55% for RIC/NMA; and NRM remained low at 9% after MAC and 8% after RIC/NMA. In this cohort of adult recipients of <7/8 MMUD PBSC grafts with PTCy-based GVHD prophylaxis enrolled on the ACCESS study, 1-year OS exceeded 80% and was comparable to 7/8 recipients. Relapse, NRM, and GVHD rates were similarly favorable and consistent with outcomes reported in 7/8 donor recipients. These findings support extending suitable MMUD match considerations to include 4-6/8 in the context of PTCy, potentially enabling near-universal donor access, while allowing for optimization of other non-HLA donor factors.
Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts
Getz, Ted M. , Pugh, Kelly , Brunner, Andrew M. , Borate, Uma , Buckstein, Rena , Hasserjian, Robert P. , Fenaux, Pierre, Sallman, David A. , Nimer, Stephen D. , Little, Richard F. , Odenike, Olatoyosi , Greenberg, Peter L. , Xu, Mina L. , Bejar, Rafael, Patnaik, Mrinal M. , Padron, Eric , Gore, Steven D. , Bennett, John M. , Metzeler, Klaus H. , Pleyer, Lisa , Loosdrecht, Arjan van de, Cluzeau, Thomas , Mufti, Ghulam, Sébert, Marie , Götze, Katharina S. , Miyazaki, Yasushi , Al‐Kali, Aref , Yacoub, Abdulraheem , Li, Bing, Stahl, Maximilian , Götze, Katharina , Brunner, Andrew, Bewersdorf, Jan Philipp , Dezern, Amy Elizabeth , Kewan, Tariq Zuheir , Platzbecker, Uwe , Sekeres, Mikkael A. , Wei, Andrew H. , Kordasti, Shahram , Roboz, Gail J. , Savona, Michael R. , Loghavi, Sanam , Fenaux, Pierre , Hourigan, Christopher S. , Porta, Matteo Giovanni Della , Santini, Valeria , Efficace, Fabio , Taylor, Justin , Kim, Tae Kon , Halene, Stephanie , Komrokji, Rami S. , Griffiths, Elizabeth A. , Xie, Zhuoer , Bejar, Rafael , Sanz, Guillermo , Figueroa, María E. , Carraway, Hetty E. , Abdel‐Wahab, Omar , Starczynowski, Daniel T. , Boultwood, Jacqueline , Daver, Naval , Churpek, Jane E. , Majeti, Ravindra , List, Alan F. , Orgueira, Adrián Mosquera , Solé, Françesc , Steensma, David P. , Adès, Lionel , Lanino, Luca , Madanat, Yazan F. , Platzbecker, Anne Sophie , Lindsley, R Coleman , Gurnari, Carmelo , Li, Bing, Kotsianidis, Ιoannis , Zeidan, Amer M.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3852-3852

10.1182/blood-2025-3852 Get It

Abstract Introduction: Standardized reporting of clinical trials results for MDS is essential to improve clinical interpretation and cross-study comparison. However, reporting of patient characteristics, response criteria, and endpoints in publications is often inconsistent; there is no systemic analysis of MDS trial reporting available. We conducted a systematic review of published MDS trial manuscripts on behalf of the international consortium for MDS (icMDS) to assess variability in reporting practices. Methods We searched ClinicalTrials.gov to identify all clinical trials registered for adults (≥18 years) with MDS that reported results between 2015-2024. Clinical trials that included acute myeloid leukemia (AML) or MDS/myeloproliferative neoplasms (MPN) were included if they enrolled ≥5 MDS patients. We excluded trials without an MDS cohort; non-therapeutic trials; trials focused on transplant interventions; or those which enrolled solid malignancies or other hematologic malignancies (chronic myeloid leukemia or lymphoid diseases). Finally, trials were required to have a manuscript available on Larvol, PubMed, or Google Scholar. Trials were categorized by disease risk (lower-risk [LR] vs. higher-risk [HR]) and trial phase (early phase [EP] vs. late phase [LP]). Results We identified 502 MDS trials on ClinicalTrials.gov, of which 351 did not meet inclusion criteria and 79 lacked a manuscript. A total of 72 trials (32 EP, 40 LP) with 80 publications (34 EP, 46 LP) were analyzed. Frequently reported baseline characteristics included age (100% EP, 100% LP), disease risk (74% EP, 74% LP), Eastern Cooperative Oncology Group performance status (85% EP, 72% LP), prior treatments (71% EP, 67% LP), and RBC transfusion dependency (32% EP, 70% LP). Less frequently reported characteristics included blood counts (hemoglobin [Hb; 38% EP, 54% LP], platelet count [38% EP, 54% LP], neutrophil count [24% EP and LP]) and bone marrow blasts (29% EP, 43% LP). Although disease risk was widely reported, definitions varied: IPSS and IPSS-R were each reported in 54% of manuscripts, while IPSS-M appeared in only 3%. Cytogenetic risk was separately reported in 39% of manuscripts (38% EP, 39% LP), and mutational data in 45% (47% EP, 43% LP). Responses per IWG 2006 criteria were reported in 84% of manuscripts. The primary endpoint involved safety/tolerability in 85% of EP manuscripts, though definitions were variable; recommended phase 2 dose was the most common (26% of EP manuscripts). In LP trials, primary endpoints were risk-specific: transfusion independence (TI) in 77% of LR, overall response rate (ORR) in 28% of HR, and complete remission (CR) or overall survival (OS) in 22% of HR. In HR manuscripts, CR was reported in 100%, ORR in 73%, hematologic improvement (HI) in 48%, RBC-TI in 23%, and OS in 80%. However, seven different definitions were used for ORR: CR + marrow CR + partial remission + HI per IWG 2006 was most common (35%). Event-free survival was reported in 25%; progression-free survival and relapse-free survival in 13%; and leukemia-free survival in 5%. Early mortality rate was reported in 35% (18% EP, 56% LP) and transplant rate in 58% (50% EP, 67% LP). Only 47% of HR and 90% of LR manuscripts identified HI-eligible patients. In LR-MDS, RBC-TI was reported in 72% of manuscripts but used six definitions. The most common were RBC-TI ≥8 weeks at any time during treatment (24%), ≥8 weeks within 28 weeks of treatment (13%), ≥8 weeks with Hb increase ≥1.0 (4%), ≥12 weeks with Hb increase ≥1.5 (4%), and ≥16 weeks within 24 weeks of treatment (12%). The remainder did not report RBC-TI, did not define it, or used a custom definition not used in another trial. HI was reported in 80% of LR papers with most of those reporting HI using IWG 2006 criteria (90%). Conclusion Reporting of baseline characteristics, response criteria, and outcomes is inconsistent in MDS clinical trials, with wide variability in response definitions, including ORR and TI. This heterogeneity limits interpretability, hampers historical comparisons and may obscure efficacy signals. Our findings highlight the need for standardized reporting guidelines to ensure clarity and consistency in MDS trial publications. As a next phase of this effort, we will conduct a formal Delphi process among icMDS experts to establish consensus recommendations for minimal and optimal MDS clinical trial reporting in manuscripts by disease risk (LR/HR) and trial phase (EP/LP).
Disparate post-relapse survival outcomes by race/ethnicity for children with B-cell acute lymphoblastic leukemia: An analysis from the recall-1 study
Berry, Abigale, Elgarten, Caitlin W. , Liu, Hongyan , Lind, Katherine , Nguyen, Gabriella, Quigg, Troy C. , Bhojwani, Deepa, Shah, Nirali, Maude, Shannon L. , Zarnegar‐Lumley, Sara , Weisnicht, Allison , Thornock, Molly, Thomas, Stéphanie , Tastet, Nicholas, Symons, Heather J. , Shoag, Jamie , Saraf, Amanda J. , Rahrig, April , Prosser-Dombrowski, Alexandra, Patel, Hiren P. , Murphy, Megan , Murphy, Lindsey , Moore‐Higgs, Giselle J., Milner, Jordan , Lee‐Miller, Cathy , Kohorst, Mira A. , Kinoshita, Hannah , Krieger, Elizabeth , Vasanna, Smitha Hosahalli, Hinson, Ashley , Hammoud, Miza Salim, Hamill, Darcy, Goode, Erin , Faulk, Kelly , Vasco, Alejandra Escobar, Elo, Lyannette, Elias, Anna , Eom, Elizabeth, Drinkwine, Jennifer, Davis, Laurie , Chu, Roland, Briscoe, Eliza, Bhatla, Deepika, Beck, Jill C., Al-Mulla, Abdulla , Ahmed, Ibrahim , Li, Yimei , Zheng, Daniel J. , Fabrizio, Vanessa A , Ortega, Maria, Rubinstein, Jeremy , Hall, Anurekha G. , Bhojwani, Deepa , Shah, Nirali N , Toner, Keri , Tastet, Nicholas, Rahim, Mahvish Qureshi , Prosser-Dombrowski, Alexandra, Pfeiffer, Thomas , Murphy, Megan, Moskop, Amy , McNerney, Kevin Owen , Hoover, Alex , Dolan, J. Gregory , Briscoe, Eliza, Winestone, Lena E. , Myers, Regina M.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4525-4525

10.1182/blood-2025-4525 Get It

Abstract Introduction Pronounced disparities in pediatric B-lymphoblastic leukemia (B-ALL) outcomes by race and ethnicity persist in the contemporary era. Gaps in overall survival (OS) from initial diagnosis are wider than event-free survival, suggesting that post-relapse mechanisms may contribute. However, data on treatment and outcomes after relapse are lacking. In a large, multicenter, real-world cohort of children and young adults with high-risk 1st relapse of B-ALL, we sought to (1) define survival outcomes by race/ethnicity and (2) explore if differences in therapy utilization drive outcomes. Methods We conducted an analysis within the Retrospective Study of Contemporary Approaches to 1st Relapse in B-ALL (ReCALL-1) cohort, which includes patients <30 years who initiated 1st relapse therapy between 2018-2022. This analysis was restricted to patients treated at US centers for “high-risk” 1st relapse, defined as relapse for which hematopoietic cell transplant (HCT) is generally standard-of-care: Early relapse (medullary <36m; isolated extramedullary <18m), late relapse with persistent end of reinduction disease, Ph+ B-ALL or age ≥18 years. Patients with Trisomy 21, those who received cell therapy before relapse and those who died during reinduction were excluded. The primary exposure was race/ethnicity categorized as Hispanic, non-Hispanic Black (NHB), non-Hispanic White (NHW), and other/unknown. The primary outcome was OS from relapse. Multivariable Cox regression models were constructed to include other social drivers of health (SDOH; health insurance, preferred language) and disease characteristics. Results Of 479 patients in ReCALL-1, 311 from 31 centers met inclusion for this analysis (41% Hispanic, 7% NHB, 46% NHW, 5% NH-other/unknown). With a median follow-up of 47m, OS differed by race/ethnicity (log-rank p=0.017): Hispanic, 4y OS 59%; NHB, 37%; NHW, 68%. Compared to NHW patients, NHB patients had an increased hazard of death (HR 2.3, 95% CI 1.3-4.3, p=0.006), while Hispanic patients were more similar to NHW patients (HR 1.3, 95% CI 0.9-2.0, p=0.16). Adjustment for SDOH only marginally attenuated the risk for NHB patients (aHR 2.0, 95% CI, 1.1-3.7, p=0.031) and led to equivalent outcomes for Hispanic patients (aHR 0.9, 95% CI, 0.5-1.5, p=0.66). Adjusting for disease characteristics that differed by race/ethnicity at p<0.2 (time to relapse, Ph+, Ph-like, KMT2Ar, age ≥18, or relapsed infant ALL) did not diminish the risk for NHB patients (aHR 2.0, 95% CI, 1.1-3.7, p=0.032) while outcomes remained equivalent for Hispanic patients (aHR 1.2, 95% CI, 0.8-1.8, p=0.40). Point estimates of cumulative incidence of non-relapse mortality (NRM) were highest in NHB patients (Hispanic, 4y NRM 13%, NHB 22%, NHW 11%), but this trend was not statistically significant (Gray’s p=0.52). Only 17% of patients initiated therapy for relapse on a clinical trial with no differences observed by race/ethnicity. Most patients received definitive treatment for relapse with either CAR T cell therapy (CART) or HCT: 79% overall, 74% Hispanic, 91% NHB, and 83% NHW. CART and HCT were utilized equally (39% and 40%, respectively) and the proportion that received each therapy did not vary by race/ethnicity. Time to CART/HCT, external referral for treatment, receipt of investigational v commercial CART, and use of post-CART consolidative HCT revealed no differences by race/ethnicity. Of the 66 patients (21%) who did not receive cell therapy, 26 had planned for CART or HCT, but did not receive due to disease progression or NRM (n=24; 12 Hispanic, 10 NHW), or insurance barriers (n=2, both Hispanic). After HCT, OS was worse for NHB patients (log-rank p=0.03) with 4y OS of 42% v 85% for NHW and 75% for Hispanic. Post-CART, 4y OS was 40% for NHB v 59% for NHW and 51% for Hispanic, but this difference was not statistically significant. Conclusion In a large real-world cohort of children with high-risk 1st relapse of B-ALL, we found a two-fold increased hazard of death for NHB patients compared to NHW patients, even after adjustment for other SDOH factors and high-risk disease features. In contrast to previous studies of adult patients, children appeared to have equal access to cell therapies across races/ethnicities. We found that Hispanic patients, who comprised >40% of the cohort, had similar survival to NHW children, suggesting that availability of cellular and immunotherapies may be mitigating historically observed disparities for children with relapsed B-ALL.
Blood board: A virtual forum for classical hematology education and care improvement
Andrade-Gonzalez, Xavier , Martin, Emma C. St. , Nwachukwu, Nneka , Pritzl, Stephanie , Ruan, Gordon , Shah, Deep , Smith, Caleb , Vijayvargiya, Pooja , Godby, Richard , Story, Charlotte McIlwaine , Marshall, Ariela L. , May, Jori E.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6420-6420

10.1182/blood-2025-6420 Get It

Abstract Introduction: The landscape of classical hematology has undergone substantial evolution over the last decade, marked by new diagnostic tools, nuanced therapeutic strategies, and an expanding understanding of underlying pathophysiology. This increasing complexity often presents unique diagnostic and therapeutic challenges. These challenges are further compounded by workforce shortages in classical hematology marked by educational gaps, geographic limitations, and difficulty accessing prompt specialty care. Unlike the well-established “Tumor Boards” in oncology, a comparable dedicated, widely accessible forum for classical hematology has largely been absent. This gap contributes to potential practice heterogeneity and isolation, especially across dissimilar care settings and geographic regions, impacting the consistent application of evidence-based practices and access to specialized expertise. To address this critical need, the “Blood Board” initiative was created to serve as an informal, virtual resource for discussing classical hematology topics and cases, fostering diverse perspectives, and collaborative problem-solving. Methods: The Blood Board was formally launched in April 2025, operating as a bi-monthly, hour-long virtual meeting conducted via non-recorded videoconferencing. The forum was designed with broad inclusivity in mind, welcoming all healthcare professionals involved in the care of adult patients with classical hematologic disorders, including trainees such as hematology/oncology fellows, academic and community-based hematologists, and any other interested providers. To date, dissemination of this initiative has been by word of mouth and e-mails containing a calendar invitation have been sent to anyone interested in participating (https://forms.gle/doyHNSx1SVFBJZmy8). To facilitate participation from various practice models and geographical locations, the virtual format was prioritized, eliminating barriers of travel and time commitment often associated with traditional in-person conferences. Participation is voluntary, encouraging an open and informal environment for de-identified case presentations, didactic discussions, and expert opinion sharing. Self-reported data on participant demographics (e.g., role, practice setting) and geographical representation have been collected to assess the initiative's reach and impact. Results: To date, sessions have consistently garnered engagement with a median of five participants in attendance at each session. There have been over 20 unique participants representing a broad spectrum of roles including both trainees and practicing hematologists/hematologist-oncologists and drawing from private practice, community-based hospitals, and academic medical centers. Over half of all participants were either in fellowship or within five years of completion of training. The virtual format has successfully overcome geographical limitations, attracting attendees from numerous states including Alabama, Florida, Georgia, Maryland, Minnesota, Missouri, Pennsylvania, South Dakota, and Wisconsin highlighting its broad appeal and potential for knowledge dissemination across a wide professional network. Conclusions: The Blood Board has demonstrated utility and met a previously unaddressed need. Sustained intellectual interest in Blood Board, coupled with a wide geographical and professional reach underscores a critical role for accessible, free, and multidisciplinary collaborative platforms in the evolving field of classical hematology. Similar to Tumor Boards, Blood Board promotes knowledge exchange and evidence-based care, garners expert support for challenging cases, and harmonizes clinical approaches, which we hope may ultimately improve patient care outcomes across diverse settings. Furthermore, this platform facilitates a national classical hematology community to support workforce development. Future goals include expanding dissemination efforts, measuring specific educational benefits, analyzing impacts on patient care, and increasing participant diversity, including recruitment of advanced practice providers and pharmacists.
CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel
McCauley, Ross, Zhang, Amy, Kota, Vamsi, Boccucci, Jacob, Grunwald, Michael, Ulrickson, Matthew, Hill, LaQuisa, Muhsen, Ibrahim, Sasine, Joshua, Advani, Anjali, Aldoss, Ibrahim, Sandhu, Karamjeet, Reshef, Ran, Luskin, Marlise, Lin, Chenyu, Cassaday, Ryan, Kopmar, Noam, Solh, Melhem, Bobillo, Silvina Odstrcil, Tsai, Stephanie, Hilal, Talal, Shah, Bijal, Faramand, Rawan, Park, Jae, Valtis, Yannis, Othman, Tamer, Vasu, Sumithira, Bezerra, Evandro, Leonard, Jessica, Tan, Virginia, O'Dwyer, Kristen, Moore, Jozal, Jamy, Omer, Mohty, Razan, Kumaran, Muthu, Hoeg, Rasmus, Stock, Wendy, Oliai, Caspian, Lill, Georgia, Schwartz, Marc, Koura, Divya, Dykes, Kaitlyn, Logan, Aaron, Daunov, Michael, Byrd, Ken, Yalniz, Fevzi, Frey, Noelle, Connor, Matthew, Yaghmour, George, Gatell, Vivian Irizarry, Jackson, Clayton, Oluwole, Olalekan, Al-Darobi, Ali, Chen, Evan, Lee, Catherine, O'Connor, Timothy, Dholaria, Bhagirathbhai, Bachanova, Veronika, Tracy, Sean, Srinagesh, Hrishikesh, Miller, Katharine, Sutherland, Katherine, Majhail, Navneet, Mountjoy, Luke, Malik, Shahbaz, Ramakrishnan, Aravind, Shaughnessy, Paul, Mathews, John, Wang, Eunice, Battiwalla, Minoo, Roloff, Gregory, Muffly, Lori, Muffly, Lori , Muffly, Lori , McCauley, Ross, Zhang, Amy, Kota, Vamsi, Boccucci, Jacob, Grunwald, Michael, Ulrickson, Matthew, Hill, LaQuisa, Muhsen, Ibrahim, Sasine, Joshua, Advani, Anjali, Aldoss, Ibrahim, Sandhu, Karamjeet, Reshef, Ran, Luskin, Marlise, Lin, Chenyu, Cassaday, Ryan, Kopmar, Noam, Solh, Melhem, Bobillo, Silvina Odstrcil, Tsai, Stephanie, Hilal, Talal, Shah, Bijal, Faramand, Rawan, Park, Jae, Valtis, Yannis, Othman, Tamer, Vasu, Sumithira, Bezerra, Evandro, Leonard, Jessica, Tan, Virginia, O'Dwyer, Kristen, Moore, Jozal, Jamy, Omer, Mohty, Razan , Kumaran, Muthu, Hoeg, Rasmus, Stock, Wendy, Oliai, Caspian, Lill, Georgia, Schwartz, Marc, Koura, Divya, Dykes, Kaitlyn, Logan, Aaron, Daunov, Michael, Byrd, Ken, Yalniz, Fevzi, Frey, Noelle, Connor, Matthew, Yaghmour, George, Gatell, Vivian Irizarry, Jackson, Clayton, Oluwole, Olalekan, Al-Darobi, Ali, Chen, Evan, Lee, Catherine, O'Connor, Timothy, Dholaria, Bhagirathbhai, Bachanova, Veronika, Tracy, Sean, Srinagesh, Hrishikesh, Miller, Katharine, Sutherland, Katherine, Majhail, Navneet, Mountjoy, Luke, Malik, Shahbaz, Ramakrishnan, Aravind, Shaughnessy, Paul, Mathews, John, Wang, Eunice, Battiwalla, Minoo, Roloff, Gregory

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2396-2396

10.1182/blood-2025-2396 Get It

Abstract Introduction: CD19-directed CAR T-cell (CAR-T) therapy has substantially improved clinical outcomes for adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). However, notable toxicities are associated with CAR-T, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Variable practice patterns have emerged regarding the use of CRS/ICANS prophylaxis (ppx) via corticosteroids and/or other pharmacologic agents, but the utility of these approaches on reducing CRS or ICANS following CAR-T in B-ALL remains unknown. Thus, we utilized the Real-World Outcomes Collaborative for CAR T in ALL (ROCCA) database to evaluate associations between ppx and the development and severity of CRS or ICANS following brexucabtagene autoleucel (brexu-cel) for B-ALL. Methods: Adult patients (pts) who received standard-of-care brexu-cel for relapsed/refractory B-ALL across 40+ US centers were included. Primary endpoints were the incidence of CRS and ICANS within 28 days of CAR-T infusion. Secondary endpoints included timing of CRS and ICANS onset, progression-free survival (PFS) and overall survival (OS). Univariable and multivariable logistic regression evaluated associations between ppx and incidence of CRS/ICANS; KM and log-rank methods were used for survival analyses. Results: A total of 378 pts were included: 53 pts (14.0%) received CRS/ICANS ppx and 325 (86.0%) received no ppx. Ppx agents included steroids only (26.4%), steroid and anakinra (52.8%), anakinra only (15.1%), and steroid and tocilizumab (5.7%). Pts in the ppx group had a higher proportion of Hispanic pts (64% vs 34%), Ph-like (36% vs 19%) and a lower proportion had 0-5% bone marrow blasts at apheresis (38% vs 53%). The ppx and no ppx groups were similar in age, prior therapies, CAR-T indication, and marrow blasts >50%. Cumulative incidence of any grade (gr) CRS was 94% with ppx and 86% with no ppx (p=0.025), of any gr ICANS was 53% with ppx and 51% with no ppx (0= 0.85). Cumulative incidence of gr 3-4 CRS was 9% in the ppx group and 10% in the no ppx group (p=1.00), of gr 3-4 ICANS was 26% in the ppx group and 29% in the no ppx group (p=0.71). Median time to onset for any gr CRS or any gr ICANS was identical in the ppx and no ppx cohorts (CRS: 5 days, range ppx 1-9 days, no ppx 0-14 days; ICANS: 7 days, ppx 1-20 days, no ppx 0-16 days). Univariate logistic regression analyses showed no significant association between ppx and the incidence of gr 2-4 CRS (OR 1.34, 95% CI: 0.75-2.40, p=0.326) or gr 3-4 ICANS (OR 0.88, 95% CI: 0.46-1.70, p=0.708). Multivariate analysis adjusting for ethnicity, leukemia genetic sub-type, and pre-apheresis disease burden similarly found no significant associations between ppx and gr 2-4 CRS (adjusted OR 1.06, 95% CI: 0.55-2.01, p=0.870) or gr 3-4 ICANS (OR 1.23, 95% CI: 0.59-2.55, p=0.584). When comparing steroid-only ppx (N=14) to steroid combinations or other drug ppx (N=39), there was no significant differences in gr 2-4 CRS (57% vs 44%, p=0.345) or gr 3-4 ICANS (43% vs 21%, p=0.115). Comparing cumulative incidence of dexamethasone (dex) exposure, pts in the ppx group had numerically greater dex exposure than pts in the no ppx group, with median (range) dosing of 182 mg (10-1386mg) and 100mg (1-4000mg), respectively. Finally, we found no significant differences in PFS or OS based on ppx. Median PFS was 9.6 months in the ppx group vs 13.3 months in the no ppx group (p=0.646) and median OS was 17.2 months in the ppx group vs 34.4 months in the no ppx group (p=0.170). Conclusions: In this large cohort of adult patients with R/R ALL receiving brexu-cel CAR-T therapy, prophylaxis intended to prevent CRS/ICANS was ineffective at reducing CRS/ICANS incidence, time to onset, or overall steroid exposure. Furthermore, PFS and OS were comparable between patients who received prophylaxis and those who did not. In the absence of prospective trials in B-ALL, these data suggest that current strategies of CRS/ICANS prophylaxis has limited benefit.
Optimal therapy for pediatric B-ALL in first relapse: Comparative effectiveness of blinatumomab to hematopoietic cell transplantation versus CD19 CAR T cell therapy
Liu, Hongyan , Shinehouse, Laura K., Hinson, Ashley , Kohorst, Mira A. , Elias, Anna , Keenan, Ella, Acres, Hannah, Ahmed, Ibrahim , Al-Mulla, Abdulla , Arthur, Laura, Beck, Jill C., Berry, Abigale, Bhatla, Deepika, Briscoe, Eliza, Chu, Roland, Davis, Laurie , Elo, Lyannette, Eom, Elizabeth, Vasco, Alejandra Escobar, Faulk, Kelly , Galán‐Gómez, Víctor , Goode, Erin , Hamill, Darcy, Vasanna, Smitha Hosahalli, Kinoshita, Hannah , Krieger, Elizabeth , Lee‐Miller, Cathy , Lind, Katherine , Milner, Jordan , Moore‐Higgs, Giselle J., Murphy, Lindsey , Murphy, Megan , Nguyen, Gabriella, Patel, Hiren P. , Prosser-Dombrowski, Alexandra, Rahrig, April , Ramachandran, Shanti , Hammoud, Miza Salim, Saraf, Amanda J. , Shoag, Jamie , Symons, Heather J. , Tastet, Nicholas, Thomas, Stephanie , Thornock, Molly, Weisnicht, Allison , Zarnegar‐Lumley, Sara , Shah, Nirali, Maude, Shannon L. , Quigg, Troy C. , Elgarten, Caitlin W. , Myers, Regina M. , Li, Yimei , Hoover, Alex , Keenan, Ella, Arthur, Laura, Briscoe, Eliza, Chang, Grace, Dolan, J. Gregory , Fabrizio, Vanessa A , Grupp, Stephan A. , Hall, Anurekha G. , Moskop, Amy , Murphy, Megan, Ortega, Maria, Ferrer, Antonio Pérez , Pfeiffer, Thomas , Rahim, Mahvish Qureshi , Toner, Keri , Shah, Nirali N , Rubinstein, Jeremy , Bhojwani, Deepa

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3339-3339

10.1182/blood-2025-3339 Get It

Abstract INTRODUCTION Outcomes for 1st relapse of pediatric B-lymphoblastic leukemia (B-ALL), especially high/intermediate-risk (HR/IR) relapse, remain unacceptably poor. Limited enrollment of this population on cooperative group clinical trials has impeded our ability to study potentially effective regimens. In the current era, patients can access innovative immunotherapies commercially. However, there is no mechanism to capture outcomes for these off-study patients and no comparative effectiveness data to guide treatment selection. METHODS We conducted a multicenter, retrospective study of patients <30 years who initiated 1st relapse therapy at a participating center from 2018-2022 (ReCALL-1 Study). Objectives were to define real-world survival outcomes, compare response rates of reinduction strategies, describe the post-reinduction treatment landscape, and, for patients with HR/IR relapse, assess the comparative effectiveness (CE) of blinatumomab to hematopoietic cell transplant (blina/HCT) v CD19 CAR T cells (CART). For the CE analysis, we emulated an open-label, randomized study of blina/HCT v CART who achieved an M1/M2 marrow at the end of an intensive reinduction (EoRI). Patients were classified by their intended treatment at EoRI. Cox regression models were used to adjust for unbalanced patient and disease features by arms. The primary outcome was overall survival (OS) from EoRI. RESULTS The full cohort included 479 patients from 33 centers (31 US, 2 international). Median time to relapse was 31 months (m); 77% had bone marrow (BM) involvement and 31% central nervous sytem involvement. With a median follow-up of 49m from relapse, 4 year (y) OS, event-free survival (EFS), and non-relapse mortality (NRM) were 64%, 43%, and 13%, respectively. Among patients with very early BM (<18m, n=79), early BM (18-35m, n=76), late BM (≥36m, n=162), and isolated CNS (n=85) relapses, 4y OS/EFS were 29%/20%, 57%/35%, 78%/49%, and 84%/61%, respectively. Only 19% received reinduction therapy on a clinical trial. Among patients with BM disease, R3 reinduction (n=179) and VXLD (n=61) had identical MRD-negative (<0.01%) CR rates of 38% (p=1.00) and equivalent treatment failure (TF; M3 or extramedullary disease) rates: R3, 8% v VXLD 7%, p=0.79. Blina (n=33) and inotuzumab-based (n=21) reinductions achieved MRD-negative CR rates of 39% and 52%, respectively, but higher TF rates of 39% and 24%. Reinduction mortality was 2%: R3, n=5; VXLD, n=3; 3-drug reinduction, n=1. Overall, as part of 1st relapse therapy, 36% received CART (78% commercial product), 44% HCT, 40% blina, and 11% inotuzumab. The emulated trial included 159 patients, 95 on blina/HCT and 64 on CART. Study arms were well matched by demographics, cytogenetics, and relapse sites, but CART patients were more likely to have relapsed <18m from diagnosis (34% v 24%) and have EoRI M2 marrows (31% v 11%), and less likely to have private insurance (36% v 51%). Unadjusted OS was comparable between arms (log rank p=0.18): CART, 60% at 4y; blina/HCT, 71%, as was NRM (10% v 13% at 4y). EFS was lower for CART (p=0.049): 4y EFS 35% v 49% for blina/HCT. After adjustment for unbalanced covariates, the hazard of death was equivalent for CART as compared to blina/HCT (aHR 1.1, 95% CI 0.6-2.1, p=0.67) and EFS became more comparable (aHR 1.3, 95% CI 0.8-2.1, p=0.22). 91% of blina/HCT and 97% of CART received their intended cell therapy; time from EoRI to cell therapy was shorter for CART (67 v 86 days, p<.001). In the CART arm, 34% underwent consolidative HCT; 1/3 were preplanned and 2/3 due to loss of B cell aplasia or NGS-MRD positivity. Of those with a 2nd relapse, CART patients were more likely to be CD19 negative (47% v 10%, p=0.003). CONCLUSION In this multicenter, real-world cohort of children treated for 1st relapse in the immunotherapy era, suboptimal outcomes for early BM relapse persisted, with particularly dismal 4y OS of 29% for relapses <18m after diagnosis. In contrast, survival for late BM and isolated CNS relapses compared favorably to historic data. Only 1 in 5 patients initiated relapse therapy on a clinical trial and although 1st relapse is not an approved indication for commercial CART in pediatrics, 36% received CART. In an emulated trial of post-reinduction blina/HCT v CART, adjusted EFS and OS were comparable, suggesting that CART may be a viable alternative to HCT for select patients. Post hoc analyses will identify whether specific subgroups may benefit more from one strategy.
KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)
Leonard, Jessica, Ladha, Abdullah, Faramand, Rawan, Roloff, Gregory, Valtis, Yannis, Tan, Virginia, Miller, Katharine, Zhang, Amy, Grunwald, Michael, Kota, Vamsi, Boccucci, Jacob, Ulrickson, Matthew, Al-Darobi, Ali, Hill, LaQuisa, Muhsen, Ibrahim, Sasine, Joshua, Advani, Anjali, Sandhu, Karamjeet, Reshef, Ran, Luskin, Marlise, Chen, Evan, Lin, Chenyu, Cassaday, Ryan, Kopmar, Noam, Solh, Melhem, Lee, Catherine, Bobillo, Silvina Odstrcil, Tsai, Stephanie, O'Connor, Timothy, Hilal, Talal, Park, Jae, Vasu, Sumithira, Bezerra, Evandro, O'Dwyer, Kristen, Moore, Jozal, Wang, Eunice, McCauley, Ross, Majhail, Navneet, Ramakrishnan, Aravind, Mountjoy, Luke, Malik, Shahbaz, Battiwalla, Minoo, Shaughnessy, Paul, Mathews, John, Srinagesh, Hrishikesh, Sutherland, Katherine, Jamy, Omer, Mohty, Razan, Kumaran, Muthu, Hoeg, Rasmus, Oliai, Caspian, Lill, Georgia, Stock, Wendy, Schwartz, Marc, Othman, Tamer, Koura, Divya, Dykes, Kaitlyn, Logan, Aaron, Daunov, Michael, Byrd, Ken, Yalniz, Fevzi, Bachanova, Veronika, Tracy, Sean, Grover, Punita, Connor, Matthew, Yaghmour, George, Gatell, Vivian Irizarry, Jackson, Clayton, Oluwole, Olalekan, Dholaria, Bhagirathbhai, Frey, Noelle, Muffly, Lori, Shah, Bijal, Aldoss, Ibrahim, Muffly, Lori , Muffly, Lori , Leonard, Jessica, Ladha, Abdullah, Faramand, Rawan, Roloff, Gregory, Valtis, Yannis, Tan, Virginia, Miller, Katharine, Zhang, Amy, Grunwald, Michael, Kota, Vamsi, Boccucci, Jacob, Ulrickson, Matthew, Al-Darobi, Ali, Hill, LaQuisa, Muhsen, Ibrahim, Sasine, Joshua, Advani, Anjali, Sandhu, Karamjeet, Reshef, Ran, Luskin, Marlise, Chen, Evan, Lin, Chenyu, Cassaday, Ryan, Kopmar, Noam, Solh, Melhem, Lee, Catherine, Bobillo, Silvina Odstrcil, Tsai, Stephanie, O'Connor, Timothy, Hilal, Talal, Park, Jae, Vasu, Sumithira, Bezerra, Evandro, O'Dwyer, Kristen, Moore, Jozal, Wang, Eunice, McCauley, Ross, Majhail, Navneet, Ramakrishnan, Aravind, Mountjoy, Luke, Malik, Shahbaz, Battiwalla, Minoo, Shaughnessy, Paul, Mathews, John, Srinagesh, Hrishikesh, Sutherland, Katherine, Jamy, Omer, Mohty, Razan , Kumaran, Muthu, Hoeg, Rasmus, Oliai, Caspian, Lill, Georgia, Stock, Wendy, Schwartz, Marc, Othman, Tamer, Koura, Divya, Dykes, Kaitlyn, Logan, Aaron, Daunov, Michael, Byrd, Ken, Yalniz, Fevzi, Bachanova, Veronika, Tracy, Sean, Grover, Punita, Connor, Matthew, Yaghmour, George, Gatell, Vivian Irizarry, Jackson, Clayton, Oluwole, Olalekan, Dholaria, Bhagirathbhai, Frey, Noelle, Shah, Bijal, Aldoss, Ibrahim

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3365-3365

10.1182/blood-2025-3365 Get It

Abstract Introduction: Brexu-cel is a highly effective treatment for R/R B-ALL, with complete responses achieved in 71% of patients (pts) treated in the pivotal ZUMA-3 trial. Patients with B-ALL with high-risk (HR) genetics are known to have inferior outcomes with chemotherapy, but little is known about the influence of HR ALL genetics on responses to chimeric antigen receptor (CAR)-T in adults. In this study, we assessed the impact of HR ALL genetics on outcomes in a large cohort of adult patients treated with brexu-cel for R/R Philadelphia chromosome (Ph)-negative B-ALL. Methods: Patient characteristics and outcomes were obtained from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) database which includes data from 40 U.S. centers. NCCN guidelines (NCCN Guidelines in Oncology, ALL v2.2025) were used to define HR B-ALL genetics; lack of HR genetics was defined as standard-risk (SR). The primary outcome was event-free survival (EFS), defined as lack of response, disease progression, or death from any cause. Secondary outcomes were overall survival (OS), relapse free survival (RFS) and response rates including complete response (CR), CR incomplete count recovery (CRi), measurable residual disease negative CR (MRD-) by flow or NGS and progressive disease (PD). Multivariable models were adjusted for age, pre-infusion blast percentage, prior allo-HCT, and post CAR-T allo-HCT (modeled as a time-varying covariate). Results: The cohort included 286 pts: 169 with HR and 117 with SR B-ALL. The HR cohort included TP53m (n=24, 14%), KMT2Ar (n=16, 9%), CRLF2r (n=65, 39%) and other HR genetics such as JAK2 and other Ph-like, IKZF1, complex cytogenetics (n=64, 38%). Relative to SR pts, HR pts were more commonly Hispanic (50% vs 28%). HR and SR pts had similar disease burden pre-apheresis (>5% blasts: 58% vs 53%), prior blinatumomab (60% vs 58%), prior inotuzumab (42% vs 46%), and prior allo HCT (27% vs 37%). The presence of CNS disease (11% HR vs 12% SR) and extramedullary disease (EMD, 22% HR vs 29% SR) at apheresis was also similar. CR/CRi was achieved in 90.5% of evaluable HR pts (n=147) and 90.2% of evaluable SR pts (n=102); MRD- rates were also similar between HR and SR pts at 78.9% and 78.2% respectively. In unadjusted analyses, EFS did not significantly differ between HR pts (median 9.6 mos; 1-yr: 46%, 95% CI 38%-54%) and SR pts (median 11.6 mos; 1-yr: 48%, 95% CI 38%- 58%). Median RFS (HR: 12.2 mos, SR: 13.3 mos) and median OS (HR: 22.4 mos, SR: 21.0 mos) were also similar. Multivariable models demonstrated no significant associations between HR B-ALL and EFS (HR 1.09, 95% CI 0.73-1.63), RFS (HR 1.13, 95% CI 0.71-1.80), or OS (HR 0.96, 95% CI 0.62- 1.48) relative to SR ALL. 28% of HR patients and 21% of SR patients underwent consolidative allo-HCT. Among the HR subgroup, CR/CRi rate was lowest in KMT2Ar (71%) relative to TP53m (95%), CRLF2r (95%), and other HR genetics (89%). The median EFS was lowest in KMT2Ar (4.1 mos), followed by TP53m (6.9 mos), CRLF2r (11.6 mos), and other HR (11.1 mos). Median OS was also lowest in KMT2Ar (6.8 mos) vs 22.4 mos in TP53m and not reached in CRLF2r or other HR. PD was highest in KMT2Ar pts (29%), as compared to 11% HR other, 10% SR, and 5% TP53 and CRLF2r. The rate of relapse among those that achieved CR across the groups was similar and ranged between 28% -40%. Rates of CD19 negative relapse were similar between all subgroups (13%-15%), however 21% of KMT2A pts underwent myeloid transformation as compared 0% for TP53 and CRLF2 pts, and 2% among other HR and SR pts. 25% of KMT2Ar patients underwent consolidative allo-HCT as compared to 32% CRLF2 pts, 29% TP53 pts, 25% other HR pts and 21% SR pts. Multivariable models evaluating the different genomic subgroups demonstrated that relative to SR B-ALL, only KMT2Ar was associated with inferior OS (HR 3.17, 95% CI 1.53-6.58, p=0020). No associations were seen between HR subgroups and EFS. Conclusion: To our knowledge, this analysis represents the largest examination of adult B-ALL recipients of CAR-T assessed by genomic risk group. We found that response rates and survival outcomes following brexu-cel were similar among HR and SR B-ALL pts, including pts with TP53m and CRLF2r. However, pts with KMT2Ar had lower response rates and dismal EFS and OS, with higher rates of PD and myeloid transformation at relapse, suggesting that alternative strategies are necessary to improve outcomes for patients with R/R KMT2Ar B-ALL.
Evaluation of the accuracy and readability of large language model responses on menopause and hormone therapy
Karam, J H, Shufelt, Chrisandra , Safwan, Nancy , Kapoor, Ekta , Christmas, Monica , Shufelt, Chrisandra L , Karam, Jana, Faubion, Stephanie S.

Mayo Clinic

Menopause | December 2, 2025 | Volume: 33 | Issue: 5 | Pages: 515-520

10.1097/gme.0000000000002695 | PMID 41329562 Get It

Objective: Generative artificial intelligence is rapidly evolving and is now being explored in health care to support patient and clinician education. This study evaluated the accuracy, completeness, and readability of four large language models (LLMs): ChatGPT 3.5, Gemini, ChatGPT 4.0, and OpenEvidence in answering questions about menopause and hormone therapy. Methods: A total of 35 questions (20 patient-level, 15 clinician-level) were entered into each LLM. OpenEvidence was only used for clinician-level questions. Four blinded expert reviewers rated responses as accurate and complete, accurate but incomplete, or inaccurate. Readability of patient-level responses was assessed using the Flesch Reading Ease Score (FRES) and word count. Analysis used ANOVA for readability, odds ratios for accuracy comparisons. Results: For patient-level questions, ChatGPT 3.5 achieved the highest accuracy (70%), followed by ChatGPT 4.0 (60%) and Gemini (30%); Gemini had significantly lower odds of accuracy compared with ChatGPT 3.5 (OR=0.18, 95% CI=0.05-0.71; P =0.014). FRES scores differed significantly ( P <0.001): Gemini scored 38.9±7.3 (“difficult”), ChatGPT 3.5 scored 31.0±11.2, and ChatGPT 4.0 scored 26.5±8.6 (both “very difficult”). For clinician-level questions, ChatGPT 4.0 achieved the highest accuracy (67%), followed by ChatGPT 3.5 and OpenEvidence (60% each) and Gemini (47%); no significant differences were observed among models (all P >0.05). Conclusion: LLMs demonstrated limited accuracy and frequent incorrect or incomplete responses to menopause-related queries, highlighting the need to improve model performance to ensure accurate and reliable information for both patients and clinicians.
Pneumonia in Immunocompromised Patients
Arora, Subodh , Walker, Stephanie M. , Cummings, Kristopher W. , Hammer, Mark M. , Arora, Silvia , Hammer, Mark M

Mayo Clinic

RadioGraphics | November 26, 2025 | Volume: 45 | Issue: 12 | Pages: No page available

10.1148/rg.250021 | PMID 41296608 Get It

By recognizing imaging patterns associated with opportunistic organisms in immunocompromised patients, radiologists can narrow the differential diagnosis and expedite treatment, reducing morbidity and mortality rates in immunocompromised patients at risk.
Phase-1 Cardiac Rehabilitation in Acute Heart Failure: Development of an Early Mobilization Algorithm Through Delphi Consensus
Satyamurthy, Akhila , Padmakumar, Ramachandran, Harikrishnan, Sivadasanpillai , Contractor, Aashish , Ozemek, Cemal , Bryant, Eryn, Ghisi, Gabriela Lima de Melo, Myers, Jonathan A. , Madan, Kushal , Supervía, Marta , Morris, Norman , Brubaker, Peter H. , Roos, Ronel , Hiser, Stephanie , Shanbhag, Vishal , Babu, Abraham Samuel , Babu, Abraham Samuel , Ramachandran, Padmakumar , Prabhu, Mukund Aravind , Jeemon, Panniyammakal , Ghisi, Gabriela Lima de Melo, Paramasivam, Ganesh , Myers, Jonathan, Hanekom, Susan D. , Yeo, Tee Joo

Mayo Clinic

Journal of Cardiopulmonary Rehabilitation and Prevention | November 26, 2025 | Volume: 46 | Issue: 1 | Pages: 58-66

10.1097/hcr.0000000000000978 | PMID 41294777 Get It

Purpose: Literature on early mobilization and exercise training in patients recovering from acute heart failure (AHF) is promising. However, there lacks uniformity in the time of initiation, exercise prescription, safety criteria, and termination criteria. Thus, the aim was to develop a mobilization algorithm for patients recovering from AHF. Methods: A modified web-based Delphi process was undertaken involving 15 panelists from across the globe. In Round 1, new variables, modifications to suggested variables, and agreement-disagreement within the panelists were obtained. In Round 2, agreement on a 5-point Likert scale was obtained. In Round 3, the algorithm was compiled, and excluded statements were discussed via web-based calls. The new variables were grouped into themes via an inductive process. The level of agreement and rating for each statement were analyzed using descriptive statistics, including frequency and percentages. We used Kappa statistics to examine the level of agreement between the panelists for each criterion. The consensus criterion was defined a priori as statements with a mean rating of ≥4 on the 5-point Likert scale by ≥70% of the panelists and Kendall’s coefficient of concordance ( W ) of ≥0.3 between panelists. Results: From Round 1, 54 new variables were obtained. More than two-thirds (118/170, 69%) of statements reached consensus and reported a fair level of agreement between panelists ( W ≥ 0.3). The final algorithm with all its criteria received a 100% (13/13) consensus. Conclusion: Physician-referral criteria, physiotherapy assessment process, exercise prescription, safety criteria, and termination criteria were formulated for early mobilization and exercise training for patients recovering from AHF.